Almeida-González L, Franco-Paredes C, Fernando Pérez L, Santos-Preciado JI

Language: Spanish
References: 36
Page: 438-450
PDF size: 426.78 Kb.

ABSTRACT

Bacterial meningitis constitutes a significant global public health problem. In particular, Neisseria meningitidis continues to be a public health problem among human populations in both developed and developing countries. Meningococcal infection is present as an endemic and an epidemic disease. Meningococcal disease is manifested not only as meningitis, but also as meningococcemia. The latter is usually fulminant. The global persistence of N. meningitidis is due to the significant number of carriers and the dynamics of transmission and disease. Approximately 500 million people worldwide are carriers of the bacterium in their nasopharynx. Multiple factors have been identified that predispose to the transmissibility of N. meningitidis, including active or passive inhalation tobacco smoking, upper viral respiratory tract infections, drought seasons, and overcrowding. These factors explain the frequent occurrence of outbreaks in military barracks, schools, prisons, and dormitories. Some of the determinants of invasiveness of the bacteria include nasopharyngeal mucosal damage in colonized individuals, virulence of the strains, absence of bactericidal antibodies, and deficiencies of the complement system. During both endemic and epidemic scenarios of meningococcal disease, control measures should include treating the cases with appropriate antimicrobial therapy (penicillin, ceftriaxone, or chloramphenicol); providing chemoprophylactic drugs to contacts (rifampin or ciprofloxacin), and close observation of contacts. Nevertheless, the key to effective control and prevention of meningococcal disease is immunoprophylaxis. Available vaccines include the polysaccharide monovalent, bivalent (serogroups A, C), or tetravalent (A, C, Y, W-135 serogroups) vaccines; conjugate vaccine (serogroup C); and the combined vaccine with outer membrane proteins and polysaccharide (serogroups B, C). Due to a recent increase in case reporting of serogroup C N. meningitidis in Mexico, we have developed a national response strategy that includes availability of vaccines and medications for chemoprophylaxis. This review aims at providing health care workers with updated information regarding the epidemiological, clinical, and preventive aspects of meningococcal disease.

REFERENCES

1. Rosenstein NE, Perkins BA, Stephens DS, Popovic T, Hughes JM. Meningococcal disease. N Engl J Med 2003, 344(18):1378-1388.

2. World Health Organization. Control of epidemic meningococcal disease. WHO Practical guidelines. 2a Ed. Disponible en: http://www.who.int/emc.

3. Peltola H. Meningococcal disease: Still with us. Rev Infect Dis 1983.5(1):71-91.

4. Tikhomirov E, Santamaría M, Estevez K. Meningococcal disease: Public health burden and control. World Health Stat Q 1997; 50(3/4):170-177.

5. Musher D. How contagious are common respiratory tract infections? N Engl J Med 2003; 348(13):1256-1266.

6. Nelson JD. Jails, microbes, and the three-foot barrier. N Engl J Med 1996; 335(12):885-886.

7. Schwartz B, Moore PS, Broome CV. Global epidemiology of meningococcal disease. Clin Microbiol Rev 1989;2 suppl:S118-S124.

8. Stephens DS. Uncloaking the meningococcus: Dynamics of carriage and disease. Lancet 1999;353:941-942.

9. Offit PA, Peter G. The meningococcal vaccine- public policy and individual choices. N Engl J Med 2003;349(24):2353-2356.

10. Pollard AJ, Santamaría M, Maiden MC. W-135 Meningococcal disease in Africa. Emerg Infect Dis 2003;9(11). Disponible en http://www.cdc.gov/ncidod/EID/vol9no11/02-0727.htm.

11. Centers for Disease Control and Prevention. Serogroup Y meningococcal disease – Illinois, Connecticut, and selected areas, United States, 1989-1996. MMWR Morb Mortal Wkly Rep 1996;43(46):1010-1014.

12. Ministerio de Salud Pública de Cuba. Enfermedad meningocócica. Cuadro Epidemiológico Nacional, Cuba, 1989. Ciudad de La Habana: MINSAP; 1990.

13. Programa Nacional de Inmunizaciones de Cuba. Aplicación de VAMENGOC-BC®. Dirección Nacional de Epidemiología. Ciudad de La Habana, Cuba: MINSAP;1991.

14. Galiano LA, Echeverry ML. Efectividad de una vacuna antimeningocócica en una cohorte de Itaguí, Colombia, 1995. Boletín Epidemiológico de Antioquia 1995;2: 20.

15. Centers for Disease Control and Prevention. Outbreaks of group B meningococcal disease – Florida, 1995 and 1997. MMWR Morb Mortal Wkly Rep 1998; 47(39):833-837.

16. Centers for Disease Control and Prevention. Control and prevention of meningococcal disease. Recommendations from the Advisory Committee on Immunization Practices (ACIP). MMWR Morb epidemiológico y recomendaciones, mayo 2002. Rev Med Uruguay 2002; 18:83-88.

17. Neal KR, Nguyen-Van-Tam JS, Jeffrey N, Slack RCB, Madeley RJ, Ait-Tahar K et al. Changing carriage rate of Neisseria meningitidis among university students during the first week of term: Cross sectional study. BMJ 2000; 320:846-849.

18. Reingold AL, Broome CV, Hightower A, Ajello GW, Bolan GA, Adamsbaum C et al. Age specific differences in duration of clinical protection after vaccination with meningococcal polysaccharide A vaccine. Lancet 1985; 2 (8447):114-118.

19. Tappero JW, Reporter R, Wenger JD, Ward BA, Reeves MW, Missbach TS et al. Meningococcal disease in Los Angeles County, California, and among men in the county jails. N Engl J Med 1996; 335(12):833-840.

20. Padron F. Meningitis meninogocóccica en los niños. Rev Med Hosp Central San Luis Potosi 1949;1:193-218.

21. Gama y Silva JJ. Meningitis cerebro-espinal en San Luis Potosí, SLP. Estudio previo químico-clínico y bacteriológico. San Luis Potosi: Ediciones de la Universidad Autónoma de San Luis Potosí; 1946:7-36.

22. Sistema Nacional de Vigilancia Epidemiológica. Anuarios de Morbilidad de la Dirección General de Epidemiología 1992-2004. Disponible en: http://www.dgepi.org.mx.

23. Cheesbrough JS, Morse AP, Green DR. Meningococcal meningitis and carriage in western Zaire: A hypo endemic zone related to climate. Epidemiol Infect 1995: 114: 75-92.

24. Mohammed I, Zaruba K. Control of epidemic meningococcal meningitis by mass vaccination. Lancet 1981;(11): 80-83.

25. Goldschneider Y, Lipow ML, Gotschlich EC, Mauck FT, Bach IF, Randolph M. Immunogenicity of group A and group C meningococcal polysaccharides in human infants. J Infect Dis 1973;128(6):769-776.

26. Gold R, Lipow ML, Goldschneider Y, Draper TL, Gotschlich EC. Clinical evaluation of group A and group C meningococcal polysaccharide vaccines in infants. J Clin Invest 1975;56:1536-1547.

27. Devine LF, Pierce WE, Floyd TM. Evaluation of group C meningococcal polysaccharide vaccines in marine recruits. Am J Epidemiol 1970;92:25-32.

28. Jennings HJ, Lugowski C. Immunochemistry of groups A, B, and C meningococcal polysaccharide tetanus toxoid conjugates. J Immunol 1981;127:1011-1018.

29. Mohammed I & Zaruba K. Control of epidemic meningococcal meningitis by mass vaccination. Lancet 1996;11:80-82.

30. Faust SN, Levin M, Harrison OB, Goldin RB, Lockhart MS, Kondaveeti S et al. Dysfunction of endothelial protein C activation in severe meningococcal sepsis. N Engl J Med 2001;345:408-416.

31. Tunkel AR, Scheld WM. Corticosteroids for everyone with meningitis? N Engl J Med 2002; 347:1613-1615.

32. Quagliarello VJ, Scheld WM. Drug therapy: Treatment of bacterial meningitis. N Engl J Med 1997;336:708-716.

33. Tabas JA, Chambas HF, Tancredi D, Binder WB, Abril V, Ortega E et al. Dexamethasone in adults with bacterial meningitis. N Engl J Med 2003;348:954-957.

34. De Moraes JC, Perkins BA, Camargo MD, Rosseto NT, Barbosa HA, Tabares C et al. Protective efficacy of serogroup B meningococcal vaccine in São Paulo, Brazil. Lancet 1992;1074-1078.

35. Zollinger WD, Mandrell RE, Griffis JM, Altieri P, Berman S. Complex of meningococcal vaccine serogroup B polysaccharide and type 2 outer membrane protein immunogenic in man. J Clin Invest 1989;63:836-848.

36. Gendrel D, Chalumeau M, Moulin F, Raymond J. Fluoroquinolones in paediatrics: A risk for the patient or for the community? Lancet Infect Dis 2003;3:537-546.